Leptin therapy for partial lipodystrophy linked to a PPAR‐γ mutation
Authors:
- 8 October 2007
- journal article
- case report
- Published by Wiley in Clinical Endocrinology
- Vol. 68 (4) , 547-554
Abstract
Summary: Aims/hypothesis Partial lipodystrophy (PL) is most commonly characterized by loss of subcutaneous fat in the extremities with preservation of truncal fat and is associated with insulin resistance, diabetes and hyperlipidaemia. Recombinant human leptin (r‐metHuLeptin) therapy has been shown to be effective in treating metabolic abnormalities associated with congenital or acquired generalized lipodystrophy and PL associated with lamin A/C (LMNA) gene mutations or highly active antiretroviral therapy (HAART). Our aim was to assess the effectiveness of leptin therapy in treating metabolic complications of PL associated with heterozygous peroxisome proliferator activated receptor gamma (PPARG) mutations. This is the first report to detail the clinical response of a patient with PL due to a PPARG mutation treated with r‐metHuLeptin.Methods A 36‐year‐old female with PL associated with a heterozygous PPARG mutation complicated by poorly controlled diabetes and severe, refractory hypertriglyceridaemia was enrolled in a National Institutes of Health (NIH) protocol to evaluate the role of r‐metHuLeptin in lipodystrophy. The patient received escalating doses of r‐metHuLeptin until a dose 0·12 mg/kg/day was reached. Metabolic parameters, including serum chemistries, fasting blood glucose, glycated haemoglobin (HbA1c), lipid profile, an oral glucose tolerance test (OGTT), an insulin tolerance test (ITT), liver volume, percentage body fat and energy expenditure were followed at regular time intervals over 18 months of therapy.Results Eighteen months of r‐MetHuLeptin therapy was associated with a marked improvement in glucose homeostasis as evidenced by normalization of the fasting blood glucose (baseline = 8·3 mmol/l; 18 months = 4·9 mmol/l), lowering of HbA1c (baseline = 9·9%; 18 months = 7·2%) and improved tolerance to an oral glucose load. In addition, a striking amelioration in the patient's refractory, severe hypertriglyceridaemia was observed (baseline = 21·15 mmol/l; 18 months = 5·96 mmol/l).Conclusion r‐MetHuLeptin is effective in treating metabolic complications associated with PL due to PPARG mutations. In the context of previously published work, our findings suggest that the response to r‐MetHuLeptin is independent of the aetiology in lipodystrophy.Keywords
This publication has 36 references indexed in Scilit:
- Long-term efficacy of leptin replacement in patients with Dunnigan-type familial partial lipodystrophyMetabolism, 2007
- Leptin Deficiency Unmasks the Deleterious Effects of Impaired Peroxisome Proliferator–Activated Receptor γ Function (P465L PPARγ) in MiceDiabetes, 2006
- A frameshift mutation in peroxisome‐proliferator‐activated receptor‐γ in familial partial lipodystrophy subtype 3 (FPLD3; MIM 604367)Clinical Genetics, 2006
- Long‐term treatment experience in a subject with Dunnigan‐type familial partial lipodystrophy: efficacy of rosiglitazoneDiabetic Medicine, 2005
- A Family with Severe Insulin Resistance and Diabetes Due to a Mutation in AKT2Science, 2004
- Leptin-Replacement Therapy for LipodystrophyNew England Journal of Medicine, 2002
- A Novel Heterozygous Mutation in Peroxisome Proliferator-Activated Receptor- Gene in a Patient with Familial Partial LipodystrophyThe Journal of Clinical Endocrinology & Metabolism, 2002
- LMNA, encoding lamin A/C, is mutated in partial lipodystrophyNature Genetics, 2000
- Localization of the gene for familial partial lipodystrophy (Dunnigan variety) to chromosome 1q21–22Nature Genetics, 1998
- Lipoatrophic diabetes: genetic exclusion of the insulin receptor geneThe Journal of Clinical Endocrinology & Metabolism, 1995